Endo pushed Opana ER as crush-proof without data — guilty plea, then Chapter 11

Endo International built itself into a large drugmaker through acquisitions, carrying more than $8 billion of debt. Its branded opioid Opana ER became a growth priority: according to the U.S. Department of Justice, from 2012 to 2013 its sales representatives touted the drug's purported crush and tamper resistance without clinical data, at times hitting demonstration pills with hammers on sales calls, and from 2011 to 2017 it concentrated marketing on the small share of prescribers writing the most opioid prescriptions.

Endo voluntarily withdrew Opana ER from the market in 2017, but the litigation kept coming. Thousands of opioid-related lawsuits from states, municipalities, tribes, and federal agencies accumulated alongside the debt. In its own August 2022 announcement, CEO Blaise Coleman described 'the thousands of opioid-related and other lawsuits that the Company has been defending at an unsustainable cost.'

On August 16, 2022, Endo filed a prearranged Chapter 11 in the Southern District of New York with a restructuring support agreement from holders of a majority of its first-lien debt: the lenders would credit-bid roughly $6 billion for substantially all assets, and voluntary trusts funded with $550 million over ten years would be established for opioid claimants.

In February 2024, Endo Health Solutions agreed to plead guilty to a misdemeanor misbranding charge — a $1.086 billion criminal fine, the second-largest set of criminal financial penalties against a pharmaceutical company, plus $450 million in forfeiture — and a $475.6 million False Claims Act settlement, with the U.S. government paid up to $464.9 million over ten years through the bankruptcy.

Over $8B debt restructured; $1.086B criminal fine, $450M forfeiture, $475.6M civil settlement; assets sold to its own lenders

It marketed Opana ER as abuse-deterrent and crush-proof without clinical data, a misbranding violation it later admitted to in a guilty plea.

It deliberately targeted the highest-volume opioid prescribers, and allegedly ignored internal concerns about pill-mill prescribing.

It carried more than $8 billion of acquisition debt, leaving no capacity to absorb litigation at an 'unsustainable cost.'

Withdrawing Opana ER in 2017 ended sales but not liability; the claims outlived the product by years.

Marketing claims the label cannot support compound quietly as legal liability; when the lawsuits arrive, the debt structure decides who owns the company.

The bankruptcy court confirmed Endo's plan in March 2024. Substantially all assets were sold to a new entity, Endo, Inc., more than 95% owned by its first-lien lenders, who had credit-bid about $6 billion. Opioid claimants' trusts are funded with $550 million over ten years, and Endo agreed to an injunction banning opioid promotion and to publish millions of internal documents in a public archive.